Neehar D. Parikh, Akbar K. Waljee, Amit G. Singal – 15 May 2015 – Downstaging can facilitate liver transplantation (LT) for patients outside of Milan criteria with hepatocellular carcinoma (HCC); however, the optimal protocol and downstaging outcomes are poorly defined. We aimed to characterize rates of successful downstaging to within Milan criteria and post‐LT recurrence and survival among patients who underwent downstaging.

Gomathy Narasimhan, Sanjay Govil, Rajesh Rajalingam, Chandrasekaran Venkataraman, Naresh P. Shanmugam, Mohamed Rela – 15 May 2015

Fatih Ozdemir, Volkan Ince, Bora Barut, Asim Onur, Cuneyt Kayaalp, Sezai Yilmaz – 15 May 2015 – Echinococcus alveolaris (EA) causes a hepatic zoonotic infection and behaves like a malignant tumor during invasion. Liver transplantation (LT) is the only curative treatment option for this unresectable disease. Here, we share our experience with living donor liver transplantation (LDLT) due to EA from the time between March 2002 and November 2014 at the Liver Transplantation Institute of İnönü University.

Todd H. Baron, Ian S. Grimm, David A. Gerber – 15 May 2015

Tim Cross, Adli Metussin – 15 May 2015

Ibtesam A. Hilmi, Daniela Damian, Ali Al‐Khafaji, Tetsuro Sakai, Joseph Donaldson, Daniel G. Winger, John A. Kellum – 15 May 2015 – Acute kidney injury (AKI) is a common complication after liver transplantation (LT). Few studies investigating the incidence and risk factors for AKI after living donor liver transplantation (LDLT) have been published. LDLT recipients have a lower risk for post‐LT AKI than deceased donor liver transplantation (DDLT) recipients because of higher quality liver grafts.

Alessandro Cucchetti, Benjamin Djulbegovic – 14 May 2015

Francesca Ceccherini Silberstein, Velia Chiara Di Maio, Marianna Aragri, Marco Ciotti, Valeria Cento, Carlo Federico Perno – 14 May 2015

Grace Lai‐Hung Wong, Yee‐Kit Tse, Vincent Wai‐Sun Wong, Terry Cheuk‐Fung Yip, Kelvin Kam‐Fai Tsoi, Henry Lik‐Yuen Chan – 14 May 2015 – Widespread and long‐term use of oral nucleos(t)ide analogs (NAs) to treat chronic hepatitis B (CHB) brings about safety data in a real‐life setting. We aimed to determine the risks of renal and bone side effects in patients receiving or who have received NAs as CHB treatment. A territory‐wide cohort study using the database from Hospital Authority, the major provider of medical services in Hong Kong, was conducted.

Lisa A. Spacek, Steven F. Solga – 14 May 2015